Search
Search Results
##search.searchResults.foundPlural##
-
VON WILLEBRAND FACTOR, ANGIODYSPLASIA AND ANGIOGENESIS
3700PDF: 1548HTML: 8015Randi Fig: 172 -
RELIABILITY OF DIFFERENT RBC INDICES AND FORMULAS IN DISCRIMINATING BETWEEN ?-THALASSEMIA MINOR AND OTHER CAUSES OF MICROCYTIC HYPOCHROMIC ANEMIA
1956PDF: 1618HTML: 14613Untitled: 203Untitled: 169 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1205PDF: 961HTML: 195 -
-
RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
3714PDF: 1635HTML: 11544Figures Haase: 189 -
MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.
4601PDF: 1302HTML: 1897Untitled: 176Untitled: 172 -
PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma
2414HTML: 259PDF: 848 -
THE HEMATOLOGICAL PARAMETERS AND BIOCHEMICAL MARKERS OF IRON STATUS IN ALFA-THALASSEMIA 3.7KB DELETION FROM METROPOLITAN REGION OF MANAUS, AMAZONAS, BRAZIL. alfa-Thalassemia 3.7 deletion From Amazonas, Brazil.
4075PDF: 594HTML: 354 -
CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL
3948PDF: 3252HTML: 190 -
The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID VEN/AZA effectively targets AML clones
1199PDF: 747HTML: 302 -
-
OUTLINE OF IRON METABOLISM, WITH EMPHASIS TO ERYTHROID CELLS iron Metabolism
1815PDF: 894Html: 300 -
FAMILIAL MEDITERRANEAN FEVER AND HYPERCOAGULABILITY
1177PDF: 702HTML: 1221 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1632PDF: 1149HTML: 235 -
HOMOZYGOUS DELETION ALFA-THALASSEMIA AND HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN, TWO GENETIC FACTORS PREDICTIVE THE REDUCTION OF MORBIDITY AND MORTALITY DURING PREGNANCY IN SICKLE CELL PATIENTS . A REPORT FROM DEMOCRATIC REPUBLIC OF CONGO ALPHA THALASSEMIA AND HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN REDUCE MORBIDITY DURING PREGNANCY IN SICKLE CELL PATIENTS
9959PDF: 969HTML: 203 -
EVALUATION OF THE PLASMA MICRO RNA EXPRESSION LEVELS IN SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
1349PDF: 671HTML: 1071Untitled: 174Untitled: 143Untitled: 124Untitled: 145Untitled: 156 -
PERIPHERAL NERVOUS SYSTEM INVOLVEMENT IN LYMPHOPROLIFERATIVE DISORDERS
1716PDF: 865HTML: 364Fig1: 223Fig.2: 244Fig. 3: 171Fig. 5: 187Fig. 4: 211 -
REFRACTORY THROMBOCYTOPENIA AND NEUTROPENIA: A DIAGNOSTIC CHALLENGE
12301PDF: 1662HTML: 4151Cover letter: 192Figure 1: 198 -
Clinical and laboratory features of Hemoglobin La Desirade variant in association with sickle cell and alpha thalassemia genes Clinical & laboratory features of Hb La Desirade trait and compound heterozygous for Hb La Desirade and HbS Hemoglobin.
1547PDF: 453HTML: 217 -
Worldwide distribution of prekallikrein (PK) deficiency: the defect seems mainly concentrated in West African countries and in the United States Worldwide distribution of PK deficiency:
1017PDF: 251HTML: 144 -
CLINICAL AND LABORATORY FEATURES OF SICKLE CELL DISEASE S/D PUNJAB: IMPACT OF HBF AND HYDROXYUREA SCD S/D Punjab
1286PDF: 1115HTML: 102 -
-
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
2785PDF: 840HTML: 6508Untitled: 219Untitled: 181Untitled: 191Untitled: 202 -
CEREBRAL VENOUS THROMBOSIS IN THE MEDITERRANEAN AREA IN CHILDREN
2483PDF: 937HTML: 2221 -
MANAGEMENT OF PORTAL VEIN THROMBOSIS IN CIRRHOTIC PATIENTS
804PDF: 535HTML: 4006 -
JUSTIFICATION OF UNIVERSAL IRON SUPPLEMENTATION FOR INFANTS 6-12 MONTHS IN REGIONS WITH A HIGH PREVALENCE OF THALASSEMIA Iron Supplementation for Infants 6-12 months in Regions with a High Prevalence of Thalassemia
2020PDF: 595Suppl. Files: 280HTML: 156 -
GILTERITINIB (XOSPATA ®) IN TURKEY: EARLY ACCESS PROGRAM RESULTS Gilteritinib (XOSPATA ®) in Turkey
1323PDF: 891Suppl. Files: 447HTML: 222 -
CHLORAMBUCIL PLUS RITUXIMAB AS FRONT-LINE THERAPY IN ELDERLY/UNFIT PATIENTS AFFECTED BY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A SINGLE-CENTRE EXPERIENCE.
3107PDF: 883HTML: 1527Fig.1 CHL-R paper: 207Fig 2 CHL-R paper: 230 -
SICKLE CELL ANAEMIA AND MALARIA
11306PDF: 6934HTML: 23811Figures Malaria and SCK: 201 -
ON THE VERSATILITY OF VON WILLEBRAND FACTOR
2758PDF: 1107HTML: 11211







